JETREA
Peakocriplasmin
BLAINTRAVITREALINJECTABLEPriority Review
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JETREA (ocriplasmin) is a recombinant protease administered via intravitreal injection for the treatment of symptomatic vitreomacular adhesion (VMA). It works by enzymatically cleaving protein components of the vitreous cortex to facilitate posterior vitreous detachment. The drug represents a non-surgical option for patients with VMA who are candidates for vitrectomy.
Peak
JETREA operates in a specialized ophthalmology niche with moderate competitive pressure; roles are likely concentrated in field medical, regional sales, and medical information teams serving retinal specialists.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Started Dec 2015
48 enrolled
Diabetic RetinopathyPosterior Vitreous DetachmentDisease Progression
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Started May 2015
62 enrolled
Vitreomacular TractionVitreomacular Adhesion
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Started Apr 2014
628 enrolled
Vitreomacular TractionVitreomacular Adhesion
Career Relevance
Careers linked to JETREA are concentrated in specialty ophthalmology commercial roles, particularly field sales and medical liaisons serving retinal practitioners and surgical centers. The peak lifecycle stage indicates stable headcount and established commercial infrastructure, making it a suitable environment for specialists in ophthalmic markets.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.